James C. Mullen's most recent trade in Thermo Fisher Scientific Inc. was a trade of 565 Common Stock done . Disclosure was reported to the exchange on May 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Thermo Fisher | James C. Mullen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 565 | 3,393 (0%) | 0% | 0 | Common Stock | |
| Thermo Fisher | James C. Mullen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 339 | 2,828 (0%) | 0% | 0 | Common Stock | |
| Thermo Fisher | James C. Mullen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 392 | 2,489 (0%) | 0% | 0 | Common Stock | |
| Thermo Fisher | James C. Mullen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 369 | 2,097 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | James C. Mullen | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2022 | 170,989 | 170,989 | - | - | Stock Option (right to buy) | |
| Editas Medicine Inc | James C. Mullen | Director, CEO | Sale of securities on an exchange or to another person at price $ 26.95 per share. | 03 Jan 2022 | 18,252 | 75,898 (0%) | 0% | 27.0 | 491,979 | Common Stock |
| Editas Medicine Inc | James C. Mullen | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 36,477 | 94,150 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | James C. Mullen | Director, CEO | Sale of securities on an exchange or to another person at price $ 38.03 per share. | 18 Oct 2021 | 13,805 | 57,673 (0%) | 0% | 38.0 | 525,033 | Common Stock |
| Editas Medicine Inc | James C. Mullen | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 36,478 | 71,478 (0%) | 0% | 0 | Common Stock | |
| Thermo Fisher | James C. Mullen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 438 | 1,728 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | James C. Mullen | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 196,637 | 196,637 | - | - | Stock Option (right to buy) | |
| Editas Medicine Inc | James C. Mullen | Director, CEO | Purchase of securities on an exchange or from another person at price $ 46.27 per share. | 02 Mar 2021 | 25,000 | 35,000 (0%) | 0% | 46.3 | 1,156,800 | Common Stock |